Intestinal inflammatory profile shows increase in a diversity of biomarkers in irritable bowel syndrome.

Background: It has been proposed that irritable bowel syndrome (IBS) is a low-grade mucosal inflammatory disease.Objective: To characterize the intestinal inflammatory profile in IBS patients with or without fructose intolerance.Design: Patients referred to colonoscopy with IBS complaints were screened for participation. IBS patients diagnosed according to the Rome II criteria and with no organic gastrointestinal disease were included in the study. One subgroup was patients included in a fructose-reduced diet study for 2 months with effects based on VAS symptom scores. Healthy controls were subjects under investigation of colorectal cancer screening with no IBS or other gastrointestinal diseases. All patients included had normal histology from rectum. Mucosal cytokines, chemokines and growth factors were measured by multiplex technology.Results: Of 27 inflammatory markers tested in the mucosal tissue, 13 were significantly increased and none was significantly decreased in IBS as compared to controls. Significantly increased were the proinflammatory cytokines tumor necrosis factor, the typical TH1 markers IFNγ, IL-1ß, IL-2 and RANTES, the typical TH2 markers IL-5 and IL-9, the TH17 marker IL-17, TNF, the pleiotropic IL-15, and the growth factors bFGF and GM-CSF. In IBS patients with fructose intolerance only IL-5 was significantly increased compared to patients without fructose intolerance.Conclusions: A dysregulated mucosal inflammatory profile with an increased level of TH1, TH2 and TH17 markers, and growth factors were observed in bowel mucosa in of IBS patients when compared to healthy controls.

Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test.

OBJECTIVES: To perform a validation of dairy registrations for use as diagnostic tool in IBS and fructose malabsorption (FM). To investigate the precision of the fructose breath test (FBT) as compared with symptom score reduction on fructose-reduced diet (FRD) in a cohort of patients with Rome II defined irritable bowel syndrome (IBS). DESIGN: IBS patients diagnosed according to the Rome II criteria and with no organic gastrointestinal disease were enrolled. The patients were randomized in an open study design with a 2 week run-in on IBS diet, followed by 4 weeks w/wo additional FRD. FBT was performed in all patients. Dairy registrations of stool frequency and consistency as well as abdominal pain/discomfort and bloating on a visual analog scale (VAS) were performed during the whole study. RESULTS: A total of 182 subjects performed the study according to protocol (88 FRD, 94 controls). The VAS symptom registration performed well in validation procedures, whereas stool data showed less impressive characteristics. FRD improved symptom scores (abdominal pain/discomfort and bloating) significantly whereas no changes were observed in the control group. The effect of FRD on the stool frequency was modest but no effect was observed on the stool consistency. The FBT did not discriminate between patients with and without effect of FRD, and even in the group with a negative FBT significant improvement of symptom scores was observed. CONCLUSION: VAS measures yield reliable symptom evaluation in dairy registrations of IBS. FRD improves symptom scores in IBS patients independent of results from the FBT.

Clinical outcomes in a prospective study of community-acquired hepatitis C virus infection in Northern Norway.

OBJECTIVE: Knowledge on the natural course of the morbidity of unselected community-acquired hepatitis C virus (HCV) infection is limited. The aim of our study was to characterize the clinical outcomes of both hepatic and extrahepatic morbidity in patients infected with HCV in a community-based setting in Northern Norway. MATERIAL AND METHODS: This prospective cohort study included 1010 HCV-positive patients diagnosed by recombinant immunoblot assay (RIBA), between 1 January 1990 and 1 January 2000. Questionnaires were sent to those physicians in Northern Norway who had requested the RIBA tests during the relevant period. Data were collected from medical records in the period between 1 January 2004 and 30 June 2006. Access to confidential information was obtained from the Norwegian Directorate of Health. RESULTS: Median age at follow-up was 39 and 41 years in females and males, respectively. In patients with positive HCV RNA status following results were found: Alanine aminotransferase was elevated in 27.4%, decompensated liver disease in 2.9% and hepatocellular carcinoma in 0.4%. Median observation period from estimated acquisition of the disease to follow-up in these patients was 26 years. Depression was reported in 10.7% of chronic infected subjects. Renal failure caused by membranoproliferative glomerulonephritis occurred in 0.2%. CONCLUSIONS: In an unselected HCV-RNA positive population severe liver disease developed in a sub-group of patients. These observations suggest that chronic HCV disease in relatively young subjects may cause a substantial burden on the health system in the future.

Self-reported dietary fructose intolerance in irritable bowel syndrome: Proposed diagnostic criteria.

AIM: To study the criteria for self-reported dietary fructose intolerance (DFI) and to evaluate subjective global assessment (SGA) as outcome measure. METHODS: Irritable bowel syndrome (IBS) patients were randomized in an open study design with a 2 wk run-in on a habitual IBS diet, followed by 12 wk with/without additional fructose-reduced diet (FRD). Daily registrations of stool frequency and consistency, and symptoms on a visual analog scale (VAS) were performed during the first 4 wk. SGA was used for weekly registrations during the whole study period. Provocation with high-fructose diet was done at the end of the registration period. Fructose breath tests (FBTs) were performed. A total of 182 subjects performed the study according to the protocol (88 FRD, 94 controls). RESULTS: We propose a new clinically feasible diagnostic standard for self-reported fructose intolerance. The instrument is based on VAS registrations of symptom relief on FRD combined with symptom aggravation upon provocation with fructose-rich diet. Using these criteria 43 of 77 patients (56%) in the present cohort of IBS patients had self-reported DFI. To improve the concept for clinical evaluation, we translated the SGA scale instrument to Norwegian and validated it in the context of the IBS diet regimen. The validation procedures showed a sensitivity, specificity and κ value for SGA detecting the self-reported DFI group by FRD response within the IBS patients of 0.79, 0.75 and 0.53, respectively. Addition of the provocation test yielded values of 0.84, 0.76 and 0.61, respectively. The corresponding validation results for FBT were 0.57, 0.34 and -0.13, respectively. CONCLUSION: FRD improves symptoms in a subgroup of IBS patients. A diet trial followed by a provocation test evaluated by SGA can identify most responders to FRD.

[Hepatitis C in Northern Norway--an 8-year material]. / Hepatitt C i nord-Norge--et åtteårsmateriale.

BACKGROUND: In 1992 a screening and medical follow-up programme of patients with hepatitis C was established in northern Norway. We report the data from the eight-year observation period. MATERIAL AND METHODS: Patients with positive recombinant immunoblot assay (RIBA) confirmation tests of hepatitis C from the counties of Nordland, Troms and Finnmark were referred from primary care. RESULTS: At the end of 1999, 1,132 RIBA positive hepatitis C patients were registered, giving an estimated prevalence of 0.24%. 236 patients were included in the follow-up study. 75% were between 17 and 39 years of age. Drug abuse was the mode of transmission in 67%. Mean age by the time of transmission was 23 years (range 12-63 years). 103 patients were treated; 136 patients did not fulfill the criteria for treatment. At the time of inclusion, 76% had no clinical symptoms. 36% treated with monotherapy and 47% treated with combination therapy had no detectable virus six months after end of treatment. INTERPRETATION: Hepatitis C infection is a disease among young people; intravenous drug abuse is the most frequent mode of transmission. The initial phase of the disease has few symptoms. A hepatitis C programme run by public health authorities is highly recommended.